India Today on MSN

Every acne details a deeper problem: Do you know yours?

Acne has been a headache for many, but the problem lies in treating it as one-size-fits-all. Dr Janaki K. Yalamanchili, ...
Medscape

Dermocosmetics in Practice: What GPs Need to Know

At SEMERGEN 2025, experts explain how dermocosmetics bridging dermatology and cosmetics can help GPs manage skin concerns, ...

The Real-Life Diet of Lukas Gage, Who Gets a New Therapist Every 6 Months

The White Lotus actor and newly minted memoirist talks “therapy roulette,” cryo spoons, and perioral dermatitis.

When bacteria breach the skin's barrier

There are a number of infections, ranging from mild to life-threatening, that can occur when certain bacteria invade the skin.

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available ...
National Institute for Health and Care Excellence

Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)

NICE is unable to make a recommendation on clascoterone (Winlevi) for treating acne vulgaris in people 12 years and over. This is because the company did not provide an evidence submission.